<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Morning Sentinel — Paper Trader</title>
    <style>
:root {
    --bg: #0e1117;
    --surface: #1a1d23;
    --surface-hover: #262730;
    --border: #333640;
    --text: #fafafa;
    --text-muted: #9ca3af;
    --green: #22c55e;
    --yellow: #eab308;
    --red: #ef4444;
    --blue: #3b82f6;
    --gray: #6b7280;
}

* { margin: 0; padding: 0; box-sizing: border-box; }

body {
    background: var(--bg);
    color: var(--text);
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    line-height: 1.6;
}

.container {
    max-width: 1200px;
    margin: 0 auto;
    padding: 24px;
}

h1 {
    font-size: 2rem;
    font-weight: 700;
    margin-bottom: 8px;
}

h2 {
    font-size: 1.4rem;
    font-weight: 600;
    margin-top: 32px;
    margin-bottom: 12px;
}

h3 {
    font-size: 1.1rem;
    font-weight: 600;
    margin-bottom: 8px;
}

p, .description {
    color: var(--text-muted);
    margin-bottom: 16px;
}

a { color: var(--blue); text-decoration: none; }
a:hover { text-decoration: underline; }

hr {
    border: none;
    border-top: 1px solid var(--border);
    margin: 24px 0;
}

.metrics-row {
    display: flex;
    gap: 16px;
    flex-wrap: wrap;
    margin-bottom: 24px;
}

.metric-box {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 16px 24px;
    min-width: 140px;
    flex: 1;
}

.metric-box .label {
    font-size: 0.85rem;
    color: var(--text-muted);
    margin-bottom: 4px;
}

.metric-box .value {
    font-size: 1.5rem;
    font-weight: 700;
}

table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 24px;
}

th {
    background: var(--surface);
    text-align: left;
    padding: 10px 12px;
    font-size: 0.85rem;
    font-weight: 600;
    color: var(--text-muted);
    border-bottom: 2px solid var(--border);
    white-space: nowrap;
}

td {
    padding: 10px 12px;
    border-bottom: 1px solid var(--border);
    font-size: 0.9rem;
}

tr:hover { background: var(--surface-hover); }

.card {
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 8px;
    padding: 20px;
    margin-bottom: 16px;
}

.card-header {
    display: flex;
    align-items: center;
    gap: 12px;
    margin-bottom: 12px;
}

.card-header .symbol {
    font-size: 1.1rem;
    font-weight: 700;
}

.card-body p {
    margin-bottom: 8px;
}

.badge {
    display: inline-block;
    padding: 2px 10px;
    border-radius: 12px;
    font-size: 0.8rem;
    font-weight: 600;
}

.badge-green { background: rgba(34,197,94,0.15); color: var(--green); }
.badge-yellow { background: rgba(234,179,8,0.15); color: var(--yellow); }
.badge-red { background: rgba(239,68,68,0.15); color: var(--red); }
.badge-gray { background: rgba(156,163,175,0.15); color: var(--gray); }
.badge-blue { background: rgba(59,130,246,0.15); color: var(--blue); }

.text-green { color: var(--green); }
.text-yellow { color: var(--yellow); }
.text-red { color: var(--red); }
.text-muted { color: var(--text-muted); }

.progress-bar {
    background: var(--surface-hover);
    border-radius: 4px;
    height: 8px;
    overflow: hidden;
    margin: 8px 0;
}

.progress-fill {
    height: 100%;
    border-radius: 4px;
    transition: width 0.3s;
}

.two-col {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 16px;
    margin-bottom: 16px;
}

.caption {
    font-size: 0.8rem;
    color: var(--text-muted);
}

.concerns-list {
    margin: 8px 0 0 16px;
}

.concerns-list li {
    color: var(--text-muted);
    margin-bottom: 4px;
}

.status-row {
    display: flex;
    gap: 8px;
    align-items: center;
    flex-wrap: wrap;
    margin-bottom: 8px;
}

.footer {
    margin-top: 48px;
    padding-top: 16px;
    border-top: 1px solid var(--border);
    font-size: 0.8rem;
    color: var(--text-muted);
}
</style>
</head>
<body>
<style>
.nav {
    background: #1a1d23;
    border-bottom: 1px solid #333640;
    padding: 0 24px;
    display: flex;
    align-items: center;
    gap: 0;
}

.nav-brand {
    font-weight: 700;
    font-size: 1rem;
    color: #fafafa;
    margin-right: 24px;
    padding: 12px 0;
    text-decoration: none;
}

.nav a {
    color: #9ca3af;
    text-decoration: none;
    padding: 12px 16px;
    font-size: 0.9rem;
    border-bottom: 2px solid transparent;
    transition: color 0.2s, border-color 0.2s;
}

.nav a:hover {
    color: #fafafa;
    text-decoration: none;
}

.nav a.active {
    color: #fafafa;
    border-bottom-color: #3b82f6;
}
</style>
<nav class="nav">
    <a href="/" style="color: #9ca3af; text-decoration: none; padding: 12px 16px 12px 0; font-size: 0.85rem; border-right: 1px solid #333640; margin-right: 16px;">jjdockins.com</a>
    <a class="nav-brand" href="index.html">$ Paper Trader</a>
    <a href="index.html">Home</a><a href="watchlist.html">Watchlist</a><a href="signals.html">Signals</a><a href="sentinel.html" class="active">Sentinel</a><a href="briefing.html">Briefing</a><a href="trading.html">Trading</a>
</nav>
<div class="container">
    <h1>Morning Sentinel</h1>
    <p class="description">Pre-market news check for BUY and WATCH stocks. Headlines from Yahoo Finance are reviewed by Claude Haiku to flag material negatives.</p>
    <hr>
    
<div class="metrics-row"><div class="metric-box">
    <div class="label">Stocks Checked</div>
    <div class="value">31</div>
</div><div class="metric-box">
    <div class="label">Clear</div>
    <div class="value" style="color: #22c55e">4</div>
</div><div class="metric-box">
    <div class="label">Warning</div>
    <div class="value" style="color: #eab308">16</div>
</div><div class="metric-box">
    <div class="label">Flag</div>
    <div class="value" style="color: #ef4444">11</div>
</div><div class="metric-box">
    <div class="label">Headlines</div>
    <div class="value">310</div>
</div></div>
<p class="caption">Model: claude-haiku-4-5-20251001 | Last run: 2026-02-11 23:52</p>
<div class="card">
    <div class="card-body">
        <p><strong>Status levels:</strong></p>
        <p><span class="text-green">Clear</span> — No material concerns. Signal stands as-is.</p>
        <p><span class="text-yellow">Warning</span> — Minor concern worth noting. Proceed with caution.</p>
        <p><span class="text-red">Flag</span> — Material negative detected. Consider pausing trades.</p>
    </div>
</div>
<hr>
<div class="card" style="border-left: 3px solid #22c55e">
    <div class="card-header"><span class="symbol">STUB</span> <span class="badge badge-green">CLEAR</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> All headlines are generic, positive articles highlighting STUB's high insider ownership and growth potential. No material negatives detected—no earnings misses, downgrades, regulatory issues, or insider selling.</p></div>
</div><div class="card" style="border-left: 3px solid #22c55e">
    <div class="card-header"><span class="symbol">RUN</span> <span class="badge badge-green">CLEAR</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> No material negatives identified. Headlines are predominantly positive, highlighting strong fundamentals (430% customer base expansion, distributed power plant growth), technical strength (golden cross, moving average breakouts), and recent momentum (12% rally). Competitor strength is noted but doesn't constitute a RUN-specific negative.</p></div>
</div><div class="card" style="border-left: 3px solid #22c55e">
    <div class="card-header"><span class="symbol">LUNR</span> <span class="badge badge-green">CLEAR</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Recent headlines are overwhelmingly positive with major catalysts (Lanteris $800M acquisition, AFRL contracts, NASA Artemis II work, institutional investment from UPenn, analyst price target hikes). No material negatives detected.</p></div>
</div><div class="card" style="border-left: 3px solid #22c55e">
    <div class="card-header"><span class="symbol">HSAI</span> <span class="badge badge-green">CLEAR</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> HSAI shows positive momentum with recent BofA Buy rating reaffirmation and price target raise to $32. No material negatives identified—headlines are predominantly bullish with strong insider ownership, valuation support, and analyst coverage.</p></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">PL</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">BUY | Score 60/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Director insider selling of $1.3M in shares raises liquidity/confidence concerns, though offset by positive government contracts (Sweden, Slovenia). Stock has surged 273% YTY, creating valuation risk if growth expectations reset.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Insider selling: Director Kristen Robinson sold 47,835 shares (~$1.3M) in January, first open-market transaction, timing coincides with stock strength</li><li>Valuation risk: 273% YTY gain suggests elevated multiples vulnerable to growth disappointment or profit-taking</li><li>High S&M spend impacting near-term margins per Jan 30 report</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">IMNM</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">BUY | Score 60/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> While Phase 3 success is genuinely positive, the stock has already surged 45-151% in recent months, creating significant momentum-driven valuation risk. Jim Cramer's cautionary stance on losses and speculative nature, combined with typical biotech binary risks around FDA approval timing, warrant caution on entry at current elevated levels.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Stock already up 45.82% in past 3 months and 131.74% YTD—substantial prior momentum limits upside in short-term swing window</li><li>Company remains unprofitable with high cash burn despite Phase 3 success, per Cramer commentary</li><li>FDA approval not guaranteed; still dependent on Q2 2026 NDA filing and regulatory decision—binary risk event</li><li>Valuation signals conflicting (P/B vs DCF per headline)—suggests potential overextension at current $22.85 price</li><li>Heavy speculative positioning post-catalyst increases risk of profit-taking pullback in 1-2 week horizon</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">FIGR</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> FIGR shows significant recent price volatility with a 27.4% decline over 7 days and 24.5% over 30 days, indicating potential momentum reversal or sector headwinds. While the company has positive catalysts (blockchain partnerships, analyst mentions), the sharp pullback and elevated valuation (P/E of 228.86) present execution risk for a 1-2 week swing trade.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Sharp recent decline: -27.4% over past 7 days, -24.5% over past 30 days suggests potential momentum loss</li><li>Extremely elevated valuation with trailing P/E of 228.86, leaving limited room for positive surprise</li><li>Stock appears overextended after 43% gain in prior month, now correcting sharply</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">OPEN</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> OPEN shows mixed signals with strong recent momentum (260% YTD, 45% in 90 days) but faces execution risk from major strategic pivot under new CEO and significant operational uncertainty. Recent 12% January drop and questions about model sustainability warrant caution for short-term traders.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>New CEO leadership transition with major operational restructuring increases execution risk in near term</li><li>Shift from asset-heavy home flipping to AI-driven asset-light model is unproven at scale with sustainability questions</li><li>Stock experienced 12% decline in January despite positive headlines, signaling underlying investor skepticism</li><li>Bearish thesis circulation and mixed options sentiment suggest divergent investor views on valuation</li><li>High volatility (IV30 at 92.57) and recent sharp pullback after strong run indicate potential mean reversion risk</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">NAVN</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> NAVN has experienced significant recent weakness (37% decline over 30 days, 33% YTD decline) with a Goldman Sachs price target cut from $30 to $22 on Jan 28. While insider buying and positive business developments (Booking.com partnership, Emirates NDC integration) are constructive, the sharp valuation compression and analyst downgrade suggest caution for near-term swing trading.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Goldman Sachs price target cut from $30 to $22 (Jan 28) while maintaining Buy suggests analyst concern about near-term valuation</li><li>37% stock decline over past 30 days indicates strong negative momentum despite positive business news</li><li>Stock trading significantly below lowest Wall Street price target of $20, suggesting potential for further weakness before recovery</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">ZETA</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> ZETA has experienced significant recent weakness (34% down in 30 days, 11.4% single-day decline) driven by sector-wide AI disruption concerns rather than company-specific negatives. While fundamentals appear solid (17 consecutive beat-and-raise quarters, strong margins, Athena momentum), the short-term momentum is fading and sector sentiment is fragile.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Sharp 30-day decline of 34% suggests broken short-term momentum despite positive fundamentals</li><li>Broad AI sector sell-off creating ongoing volatility risk with 'AI replacement' narrative at fever pitch</li><li>6.76% single-day decline and negative returns over multiple timeframes indicate weakness persists</li><li>Sector-wide headwinds may continue to pressure stock regardless of company-specific positive developments</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">W</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> W shows positive partnership momentum with Affirm expansion, but recent price action reveals sharp pullbacks (-17.8% over 7 days, -19.4% over 30 days) that suggest weakening short-term momentum despite strong long-term gains. Valuation uncertainty and mixed near-term sentiment pose swing-trade timing risks.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Sharp recent price declines (17.8% over 7 days, 19.4% over 30 days) indicate deteriorating short-term momentum</li><li>Mixed sentiment on valuation at current levels ($88-$103 range) with analysts questioning opportunity vs. risk</li><li>Recent 1-day and weekly declines suggest loss of upside momentum despite positive partnership news</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">LEU</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> LEU posted a significant earnings miss (-44.52% EPS surprise) and has experienced sharp recent declines (16.4% in 7 days, 32% in 30 days), though a $900M HALEU contract award and positive 2026 guidance provide some offset. The stock is volatile and may face near-term headwinds from the earnings miss despite longer-term positives.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Q4 2025 EPS miss of 44.52% despite revenue beat</li><li>Sharp 16.4% pullback over past 7 days and 32% over 30 days suggests momentum reversal</li><li>Significant drop in uranium revenue noted in earnings coverage</li><li>Stock weakness despite $900M contract award indicates investor skepticism on near-term execution</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">GRAL</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> GRAL has experienced a massive 186% one-year surge and shows recent 7-day/30-day declines of 6.7% and 9.4%, suggesting momentum loss and potential overvaluation after the rally. While fundamentals appear solid with revenue growth and partnerships, the sharp recent pullback combined with stretched valuation warrants caution for short-term swing trades.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Stock down 6.7% last 7 days and 9.4% last 30 days despite positive catalysts, indicating momentum reversal</li><li>Massive 186% one-year gain creates elevated risk of profit-taking and mean reversion on short timeframe</li><li>Valuation stretched after 300%+ gains in 2025; analyst price targets ($110-$115) only 17-22% above current $94 level, limiting upside</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">MP</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> MP has strong fundamental catalysts (DoD investment, 10-year offtake, Project Vault) and insider buying support, but recent volatility around government policy signals and valuation concerns after a 224% 2025 rally suggest near-term choppiness. Stock tanked on Feb 4 when officials discussed critical minerals policy, indicating sentiment sensitivity.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Sector-wide volatility tied to policy announcements (Trump administration signals on price controls and critical minerals causing sharp daily swings)</li><li>Valuation stretched after 224% 2025 rally; Feb 6 article questions if current price is justified</li><li>Policy-dependent upside creates headline-driven volatility risk for 1-2 week swing trades</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">SEI</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> SEI shows strong bullish momentum with major AI data center contracts and analyst upgrades, but the stock has already rallied 53% YTD with a high trailing P/E of 57.34, creating significant valuation risk and potential pullback exposure for a 1-2 week swing trade.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>High valuation at P/E 57.34 after 53% YTD rally increases pullback risk</li><li>Stock may be overextended after recent sharp gains (14.64% in one week), creating squeeze-out risk for late entries</li><li>Regulatory debate mentioned but not detailed - potential headwind in energy sector</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">RH</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> RH shows significant volatility and sector headwinds with a 52.6% one-year decline and recent 13% weekly pullback. However, no specific earnings misses, downgrades, regulatory issues, or insider selling are reported. Mixed sentiment with some bullish thesis countered by consumer spending concerns.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Sector-wide retail headwinds as e-commerce takes share from brick-and-mortar</li><li>High sensitivity to consumer spending and housing demand weakness</li><li>Recent sharp pullback (13% over 7 days, 12.9% over 1 week) suggests momentum fading</li><li>52.6% one-year decline indicates sustained bearish sentiment despite recent relief rally</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">ALMS</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> ALMS has experienced exceptional momentum (361.9% YTD, 250% YoY) with positive Phase 3 data and insider buying support, but valuation has extended significantly with one fund selling a $5M stake recently. Extended rallies carry elevated mean-reversion risk in biotech swing trades.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Extreme valuation extension after 361.9% YTD gain and 250%+ YoY surge increases reversal risk</li><li>Fund liquidation of $5M stake signals some profit-taking by institutional investors</li><li>Clinical-stage biotech dependent on regulatory approval (FDA path for envudeucitinib) introduces execution risk</li><li>Stock already up 46% in past month, limiting further near-term upside for 1-2 week swing horizon</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">TXG</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> TXG has earnings report scheduled for tomorrow (Feb 13) with analyst expectations pointing to negative earnings. While recent momentum is strong (40% in 1 month), pre-earnings uncertainty and analyst pessimism create risk for a 1-2 week swing position.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Earnings report imminent (tomorrow after market close) with analyst consensus expecting negative earnings</li><li>Multiple articles flag TXG as lacking 'right combination' for earnings beat, creating high volatility risk around report</li><li>Recent 40%+ momentum may reflect speculative positioning ahead of earnings disappointment</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">SBSW</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> While SBSW shows positive momentum with recent price strength and analyst upgrades, a $3.6B loss at a major mining competitor signals sector-wide headwinds in platinum operations that could pressure sentiment. Gold tailwinds are present but platinum exposure creates near-term volatility risk.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Platinum sector weakness: Mining giant posted $3.6B loss, creating potential sector contagion despite gold strength</li><li>Commodity price dependency: Stock momentum heavily tied to gold/platinum prices which are volatile and cyclical</li></ul></div>
</div><div class="card" style="border-left: 3px solid #eab308">
    <div class="card-header"><span class="symbol">BBAR</span> <span class="badge badge-yellow">WARNING</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Mixed signals with recent analyst upgrades offsetting earlier downward revisions and a significant Q3 net income drop. Macro-dependent emerging market bank with high volatility and currency exposure risks for a 1-2 week swing trade.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Significant drop in Q3 net income despite revenue of $1.21B - earnings quality concern</li><li>High analyst volatility: price target swung from ARS 9,663 down to 7,817 then up to 11,606 within weeks</li><li>Emerging market bank heavily exposed to Argentine macroeconomic and political risk</li><li>Stock is highly volatile and sentiment-driven (40%+ swings on political events); difficult to predict short-term direction</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">HOOD</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">BUY | Score 65/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> HOOD reported Q4 revenue miss versus analyst expectations, causing the stock to decline as much as 13% intraday on Feb 11—its largest single-day drop since April 2025. This is a material negative catalyst for a 1-2 week swing trade window.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Q4 2025 revenue missed analyst expectations</li><li>Stock down 9-13% intraday following earnings miss</li><li>Largest intraday decline since April 2025 signals strong negative market reaction</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">UPST</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">BUY | Score 65/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> CEO stepping down effective May 1 creates near-term leadership uncertainty despite beating earnings. Stock already down 13%+ on the news, indicating market is pricing in significant concern about the transition.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>CEO Dave Girouard stepping down May 1 with CTO Paul Gu taking over - leadership transition risk</li><li>Stock already down 13%+ on announcement day despite beating revenue and guidance estimates - suggests market uncertainty overrides positive fundamentals</li><li>Margin challenges noted alongside leadership transition creates execution risk during critical leadership period</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">ASTS</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">BUY | Score 60/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Multiple material negatives converge: analyst concerns about declining estimate revisions and rising costs, significant insider selling ($9.7M), and competitive pressures from AT&T/Amazon partnership. Stock volatility and -5.73% recent decline suggest headwinds ahead.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Falling 2025-26 earnings estimates and rising operational costs creating valuation pressure</li><li>Insider selling of $9.7M suggests insiders may lack conviction at current levels</li><li>AT&T/Amazon satellite partnership signals competitive threat to ASTS market opportunity</li><li>23.6% decline over 7 days indicates momentum shift despite BlueBird 6 deployment success</li><li>Stock already up 346% over 5 years - significant gains already priced in</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">HYMC</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">BUY | Score 60/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Extreme volatility (24% down past week after 442% gain in 90 days), overvaluation concerns, and pending equity dilution via $163M shelf offering create material short-term risk. Stock is highly commodity-dependent with sharp reversals tied to precious metals prices.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Extreme volatility: 24% decline past week after massive run-up; price swings of 11-19% in single days</li><li>Valuation risk: Morningstar rates HYMC 67% overvalued despite technical momentum</li><li>Equity dilution: $163.24M shelf registration filed for 4.7M shares; dilution pressure when exercised</li><li>Commodity price dependency: Stock moves 11-19% daily based on gold/silver price fluctuations; high beta risk</li><li>Governance concern: Reduction of quorum for shareholder meetings raises red flags for minority investors</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">IONQ</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> Multiple material negatives converge: short-seller allegations of misleading practices and Pentagon revenue reliance, dilutive equity raises funding unprofitable operations, and sector-wide valuation concerns (57x sales). Recent 4.5-8.5% daily drops signal negative momentum.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Short-seller report (Wolfpack Research) alleging misleading Pentagon contract revenues and insider selling</li><li>Dilutive share issuances to fund acquisitions while company remains unprofitable</li><li>Terminated Pentagon contracts reportedly drove majority of recent revenues</li><li>Extreme valuation (57x sales) with no clear path to profitability</li><li>Negative technical momentum with 4.5-8.5% single-day declines and 60% drawdown from highs</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">RGTI</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> RGTI has experienced a 23% YTD decline following a roadmap reset and soft results, with a delayed flagship product launch (Cepheus-1-108Q) signaling execution challenges. Competitive pressures from IonQ's acquisition strategy add to near-term uncertainty.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Roadmap reset and delayed Cepheus-1-108Q product launch indicates technical/execution risks</li><li>23% YTD decline and recent negative price moves suggest momentum weakness</li><li>Increased competitive pressure from IonQ's hardware manufacturing acquisition</li><li>Company described as loss-making with soft recent results</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">HIMS</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> HIMS faces material legal and regulatory headwinds with an active patent lawsuit from Novo Nordisk, FDA regulatory pressure forcing product withdrawal, and analyst downside warnings. Stock has already dropped 55.8% in 3 months, signaling significant near-term selling pressure.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Active patent lawsuit filed by Novo Nordisk over compounded semaglutide with 'very significant' damages claim</li><li>FDA regulatory crackdown forcing HIMS to halt compounded semaglutide pill offering days after launch</li><li>Bank of America analysts citing 'significant further downside' in HIMS stock</li><li>Core competitive advantage in GLP-1 market being eroded by legal/regulatory actions</li><li>Stock momentum deeply negative with 55.8% drop over 3 months preceding further losses</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">FLNC</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> FLNC experienced a severe 35-36% stock price decline following Q1 earnings that missed expectations with widened losses and margin pressures. Despite reaffirmed guidance and record backlog, the market's sharp negative reaction and ongoing profitability concerns create material risk for a 1-2 week swing trade.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Q1 revenue and GAAP EPS missed Wall Street expectations with significant negative market reaction</li><li>Net loss widened to $45.07M in Q1 2026 vs prior year, indicating deteriorating profitability</li><li>Stock down 35-36% post-earnings with investors spooked by higher losses</li><li>Discrete project cost overruns cited by management suggest execution risk despite backlog strength</li><li>Margin pressure and seasonality headwinds create near-term profitability headwinds</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">NTSK</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 55/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> NTSK has experienced a steep 27.8% decline over 30 days and 28.9% YTD decline, with multiple analyst price target cuts (RBC from $27 to $23, KeyBanc from $28 to $24). CFO insider selling of $856K adds conviction to downward momentum and suggests management concern about valuation.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Significant insider selling: CFO sold $856K in stock in January</li><li>Multiple analyst price target cuts despite positive earnings (RBC and KeyBanc both lowered targets)</li><li>Sharp recent decline: 19.1% drop in past 7 days, 27.8% in past 30 days</li><li>Valuation reset from IPO enthusiasm with stock trading below IPO price</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">HUT</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> HUT experienced a 17.9% single-day drop on Feb 6 driven by sector-wide Bitcoin weakness and Treasury concerns. The stock faces material near-term headwinds from crypto market volatility and conflicting strategic shifts that could pressure sentiment in the 1-2 week swing window.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>17.9% single-day decline on Feb 6 due to Bitcoin price collapse and Treasury Department uncertainty regarding crypto support</li><li>Sector-wide Bitcoin mining/crypto selloff affecting comparable stocks (MARA, RIOT down 7-14%)</li><li>Strategic pivot from crypto mining to AI data centers creates execution risk and potential investor confusion</li><li>Local environmental and community concerns over 500MW NY data center proposal could create permitting/regulatory delays</li><li>Bitcoin volatility directly correlates to HUT price movement; near-term crypto sentiment remains fragile</li></ul></div>
</div><div class="card" style="border-left: 3px solid #ef4444">
    <div class="card-header"><span class="symbol">ALAB</span> <span class="badge badge-red">FLAG</span> <span class="text-muted">WATCH | Score 35/100 | 10 headlines</span></div>
    <div class="card-body"><p><strong>Reasoning:</strong> ALAB reported strong Q4 earnings and revenue beats, but stock is plummeting due to margin concerns and dilution from new Amazon warrant issuance. Material negative catalysts on earnings day create significant near-term downside risk for a 1-2 week swing trade.</p><p><strong>Concerns:</strong></p><ul class="concerns-list"><li>Earnings day margin concerns sparked investor selling despite beating estimates</li><li>Company issued new warrants for Amazon, creating shareholder dilution</li><li>Stock plunging below key support levels despite strong Q4 fundamentals indicates broken momentum</li><li>Stock has surged 109% YoY and 26.4% in past week, suggesting profit-taking and valuation concerns</li></ul></div>
</div>

    <div class="footer">
        Paper Trader — Static export generated 2026-02-13 23:19
    </div>
</div>
</body>
</html>